EDAP TMS S.A. (NASDAQ: EDAP ) Q4 2024 Earnings Conference Call
Company Participants
- John Fraunces – IR, LifeSci Advisors
- Ryan Rhodes – CEO
- Ken Mobeck – CFO
Conference Call Participants
- Michael Sarcone – Jefferies
- Swayampakula Ramakanth – H.C.
EDAP TMS S.A. (NASDAQ: EDAP ), a leader in therapeutic ultrasound, reported its fourth-quarter 2024 earnings on March 27, 2025, at 8:30 AM ET. The company’s CEO, Ryan Rhodes, and CFO, Ken Mobeck, provided an update on EDAP’s financial performance and business developments during the call.
Rhodes began the call by highlighting the company’s strong sales growth in the fourth quarter, driven by the continued success of its flagship product, Focal One. He also mentioned the expansion of the company’s commercial footprint in the US and Europe, as well as the successful integration of the Sonoblate II system into the company’s product portfolio.
Moving on to the financials, Mobeck reported a 20% increase in revenue for the quarter, reaching €45.3 million. The net loss for the period was €12.3 million, an improvement from the €18.7 million loss reported in the same quarter the previous year. The CFO attributed the improvement to higher sales and cost control measures.
During the Q&A session, Michael Sarcone of Jefferies asked about the company’s plans for expanding its product portfolio beyond urology. Rhodes responded by mentioning ongoing research and development efforts in other indications, such as gastroenterology and neurosurgery.
Swayampakula Ramakanth of H.C. inquired about the potential impact of regulatory changes on EDAP’s business. Rhodes reassured investors that the company is well-positioned to navigate any regulatory challenges, thanks to its strong relationships with regulatory authorities and its robust clinical data.
Impact on Individuals
For individuals with prostate cancer, the strong sales growth of EDAP’s Focal One system is welcome news. This innovative technology offers a less invasive and more precise alternative to traditional prostate cancer treatments, leading to better outcomes and improved quality of life for patients.
Impact on the World
The continued success of EDAP’s Focal One system represents a significant step forward in the treatment of prostate cancer. With its precision and minimally invasive nature, this technology has the potential to reduce the overall burden of prostate cancer on healthcare systems and improve the lives of countless patients around the world.
Conclusion
EDAP TMS S.A.’s Q4 2024 earnings call provided investors with an encouraging update on the company’s financial performance and business developments. The strong sales growth of the Focal One system, combined with ongoing R&D efforts in new indications, positions EDAP well for future growth. For individuals with prostate cancer, this technology offers a less invasive and more precise alternative to traditional treatments, leading to better outcomes and improved quality of life. For the world, the continued success of Focal One represents a significant step forward in the treatment of prostate cancer, with the potential to reduce the overall burden of this disease on healthcare systems and improve the lives of countless patients.
